Raul Cordoba/X
Jun 29, 2025, 14:28
Raul Cordoba Highlights Study on Performance of CHA2DS2-VASc and HAS-BLED in Predicting Stroke and Bleeding in Atrial Fibrillation and Cancer
Raul Cordoba, Associate Chief at the Department of Hematology at Jiménez Díaz Foundation, shared a post on X:
“Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer.
“The CHA2DS2-VASc score had good to modest discrimination in haematological cancer AUC = 0.71 (0.66, 0.76), compared with no-cancer AUC = 0.73 (0.72, 0.74)
HAS-BLED discrimination was poor in haematological cancer AUC = 0.59 (0.55, 0.64), compared with no-cancer AUC = 0.61 (0.60, 0.62)”
Title: Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer
Authors: Alyaa M Ajabnoor, Salwa S Zghebi, Rosa Parisi, Darren M Ashcroft, Corinne Faivre-Finn, Mamas A Mamas, Evangelos Kontopantelis
Read the full article.
Stay updated with Hemostasis Today.
-
Aug 27, 2026, 16:51Michelle M: The Power of Community in Bleeding Disorders
-
Aug 27, 2026, 16:37Chris Baugh: Stabilize Measure Decide Managing Residual FXa Inhibitor Effects in Urgent Care
-
Aug 27, 2026, 16:26Aurelio Maggio: New Perspectives in The Treatment of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 27, 2026, 16:24Bruno Pougault : Refrigerated Platelets Could Transform Hemorrhage Management
-
Aug 27, 2026, 16:20Women’s Equality and the Fight for Equitable Healthcare – Hemophilia Federation of America
-
Aug 27, 2026, 16:16Thomas Georgas: HIT Requires More Than a Platelet Count
-
Aug 27, 2026, 15:59Leslie Iverson: What Does a Zero CAC Score Really Mean?
-
Aug 27, 2026, 15:42Shahram Raza Shouq: Small Steps Toward a Thalassaemia-Free Future
-
Aug 27, 2026, 15:27Dai H. Chung: A New Foundation for Studying Pediatric Pulmonary Embolism